Management Changes Influenced by PET by Clinical Indication
| Management change influenced by PET | Limited metastases (n = 34) | Rising markers (n = 20) | Symptoms (n = 17) | New mass (n = 12) | Disease extent (n = 11) | Residual mass (n = 8) | Total (n = 102) |
|---|---|---|---|---|---|---|---|
| Treatment planning* | 0 | 0 | 2 | 0 | 4 | 0 | 6 |
| Active to observation | 0 | 0 | 3 | 0 | 0 | 2 | 5 |
| Active to supportive | 7 | 1 | 3 | 0 | 0 | 0 | 11 |
| Observation to active | 0 | 10 | 1 | 0 | 0 | 1 | 12 |
| Varied active | 13 | 2 | 3 | 5 | 1 | 2 | 26 |
| Total changed | 20 (59) | 13 (65) | 12 (71) | 5 (42) | 5 (45) | 5 (63) | 60 (59) |
↵* Patients for whom referring clinician was not prepared to prospectively commit to a treatment plan without access to PET findings.
Numbers in parentheses are percentages.